论文部分内容阅读
Ｓｃｏｔｉａ公司提交ＥＦ１３和ＥＦ４上市申请Ｓｃｏｔｉａ公司在英国、丹麦和爱尔兰提交了γ－亚油酸锂产品（ＥＦ１３）的首次上市申请，该药用于治疗胰腺癌。英国很快会批准ＥＦ４的申请，ＥＦ４是一种脂质混合物（含ＧＬＡ和亚油酸），用于治疗糖尿病性神经病（ｄｉ...
Scotia Submits EF13 and EF4 Listing Applications Scotia has filed its first public listing of lithium-lithium-linoleate products (EF13) in the United Kingdom, Denmark and Ireland for the treatment of pancreatic cancer. The UK will soon approve the application for EF4, a lipid blend containing GLA and linoleic acid for the treatment of diabetic neuropathy.